Prognostic Value of CD9 in Solid Tumor: A Systematic Review and Meta-Analysis

Numerous clinical studies investigated how low expression of CD9 predicts poor prognosis of solid tumor. However, the results were inconclusive. This present meta-analysis was therefore performed to determine the prognostic value of CD9 expression in solid tumors. In this meta-analysis, 25 studies i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ping Zeng, Meng Si, Rui-xia Sun, Xu Cheng, Xiao-yang Li, Min-bin Chen
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	CD9 solid tumors prognosis overall survival time to progression Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/17d46abba540471eac339dd3aedc15de
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:17d46abba540471eac339dd3aedc15de
record_format	dspace
spelling	oai:doaj.org-article:17d46abba540471eac339dd3aedc15de2021-11-19T05:17:09ZPrognostic Value of CD9 in Solid Tumor: A Systematic Review and Meta-Analysis2234-943X10.3389/fonc.2021.764630https://doaj.org/article/17d46abba540471eac339dd3aedc15de2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.764630/fullhttps://doaj.org/toc/2234-943XNumerous clinical studies investigated how low expression of CD9 predicts poor prognosis of solid tumor. However, the results were inconclusive. This present meta-analysis was therefore performed to determine the prognostic value of CD9 expression in solid tumors. In this meta-analysis, 25 studies involving 5,555 participants were included; the result showed strong significant associations between declined expression of CD9 and all endpoints: overall survival (OS) (hazard ratio (HR) = 1.88, 95% CI = 1.45–2.43, p < 0.000) and time to progression (TTP) (HR = 2.0, 95% CI = 1.38–2.88, p < 0.000). The subgroup analysis was also performed, which revealed that the associations between CD9 downregulated expression related to poor OS in lung cancer and head and neck cancer. Also, low expression of CD9 was significantly connected with poor TTP in patients with head and neck cancer. The adverse prognostic impact of decreased expression of CD9 was observed in patients of different ethnicities. In conclusion, these results showed that declined expression of CD9 was associated with poor survival in human solid tumors. CD9 may be a valuable prognostic predictive biomarker and a potential therapeutic target in human solid tumors.Ping ZengMeng SiRui-xia SunXu ChengXiao-yang LiMin-bin ChenFrontiers Media S.A.articleCD9solid tumorsprognosisoverall survivaltime to progressionNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	CD9 solid tumors prognosis overall survival time to progression Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	CD9 solid tumors prognosis overall survival time to progression Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Ping Zeng Meng Si Rui-xia Sun Xu Cheng Xiao-yang Li Min-bin Chen Prognostic Value of CD9 in Solid Tumor: A Systematic Review and Meta-Analysis
description	Numerous clinical studies investigated how low expression of CD9 predicts poor prognosis of solid tumor. However, the results were inconclusive. This present meta-analysis was therefore performed to determine the prognostic value of CD9 expression in solid tumors. In this meta-analysis, 25 studies involving 5,555 participants were included; the result showed strong significant associations between declined expression of CD9 and all endpoints: overall survival (OS) (hazard ratio (HR) = 1.88, 95% CI = 1.45–2.43, p < 0.000) and time to progression (TTP) (HR = 2.0, 95% CI = 1.38–2.88, p < 0.000). The subgroup analysis was also performed, which revealed that the associations between CD9 downregulated expression related to poor OS in lung cancer and head and neck cancer. Also, low expression of CD9 was significantly connected with poor TTP in patients with head and neck cancer. The adverse prognostic impact of decreased expression of CD9 was observed in patients of different ethnicities. In conclusion, these results showed that declined expression of CD9 was associated with poor survival in human solid tumors. CD9 may be a valuable prognostic predictive biomarker and a potential therapeutic target in human solid tumors.
format	article
author	Ping Zeng Meng Si Rui-xia Sun Xu Cheng Xiao-yang Li Min-bin Chen
author_facet	Ping Zeng Meng Si Rui-xia Sun Xu Cheng Xiao-yang Li Min-bin Chen
author_sort	Ping Zeng
title	Prognostic Value of CD9 in Solid Tumor: A Systematic Review and Meta-Analysis
title_short	Prognostic Value of CD9 in Solid Tumor: A Systematic Review and Meta-Analysis
title_full	Prognostic Value of CD9 in Solid Tumor: A Systematic Review and Meta-Analysis
title_fullStr	Prognostic Value of CD9 in Solid Tumor: A Systematic Review and Meta-Analysis
title_full_unstemmed	Prognostic Value of CD9 in Solid Tumor: A Systematic Review and Meta-Analysis
title_sort	prognostic value of cd9 in solid tumor: a systematic review and meta-analysis
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/17d46abba540471eac339dd3aedc15de
work_keys_str_mv	AT pingzeng prognosticvalueofcd9insolidtumorasystematicreviewandmetaanalysis AT mengsi prognosticvalueofcd9insolidtumorasystematicreviewandmetaanalysis AT ruixiasun prognosticvalueofcd9insolidtumorasystematicreviewandmetaanalysis AT xucheng prognosticvalueofcd9insolidtumorasystematicreviewandmetaanalysis AT xiaoyangli prognosticvalueofcd9insolidtumorasystematicreviewandmetaanalysis AT minbinchen prognosticvalueofcd9insolidtumorasystematicreviewandmetaanalysis
_version_	1718420359609319424

Prognostic Value of CD9 in Solid Tumor: A Systematic Review and Meta-Analysis

Ejemplares similares